propantheline (Pro-Banthine)

Introduction

Tradename: Pro-Banthine.

Indications

• adjunctive therapy for peptic ulcer disease
• irritable bowel disease
• used in conjunction with H2 receptor antagonists in the treatment of Zollinger-Ellison syndrome
• urinary incontinence

Dosage

15 mg PO 30 min QAC & QHS

Tabs: 7.5 & 15 mg.

Pharmacokinetics

• quaternary ammonium drug with variable GI absorption, depending upon presence of food
• distribution is unknown, but does NOT readily penetrate CNS
• elimination 1/2life is 9 hours

elimination via liver

elimination via kidney

1/2life = 9 hours

Adverse effects

• common (> 10%)
  • constipation
  • decreased sweating,
  • dry mouth, skin, nose or throat
• less common (1-10%)
  • difficulty swallowing
• uncommon (< 1%)
  • rash, confusion, increased intraocular pressure, bloating, blurred vision, headache, loss of memory, nausea/vomiting, weakness, tiredness, urinary retention, tachycardia, drowsiness, nervousness, insomnia
• cholinergic effects:
  • dry mouth
  • constipation
  • urinary retention

• drug adverse effects of parasympatholytics

Mechanism of action

• not fully understood
• may act as nonselective smooth muscle relaxant
• little or no muscarinic activity, except at very high doses

More general terms

• antiulcer agent
• parasympatholytic (anticholinergic, antimuscarinic agent)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=4934
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=9279
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=156863
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=443396
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=521275